Background: Pinitol is thought to mediate insulin action and improve insulin resistance. We evaluated the effects of pinitol on glycemic control, insulin resistance and adipocytokine levels in type 2 diabetic patients. Material and Method: A total of 66 patients with type 2 diabetes who had been taking oral hypoglycemic agents for at least 3 months were enrolled and randomized to receive pinitol (n = 33) or matching placebo (n = 33). All subjects took 1,200 mg pinitol or placebo and maintained their current oral hypoglycemic agents throughout the study. Results: Mean HbA1c, fasting plasma glucose, and HOMA-IR were significantly lowered more in patients taking pinitol than in those given a placebo. Patients who had an HbA1c over 8.0% showed a greater reduction (p < 0.01) than those who had an HbA1c below 8.0% (p =0.16). In addition, in the group of patients with a HOMA-IR over 2.5, there was a significant decrease in HbA1c compared to that in the group of patients with a HOMA-IR below 2.5. There were no differences in the changes in adiponectin, FFA and CRP between the two groups. Conclusions: Pinitol can mediate insulin action to improve glycemic control and insulin sensitivity in patients with type 2 diabetes mellitus, especially in patients with insulin resistance.

Varela-Nieto I, Leon Y, Caro HN: Cell signalling by inositol phosphoglycans from different species. Comp Biochem Physiol B Biochem Mol Biol 1996;115:223–241
Paneda C, Villar AV, Alonso A, et al: Purification and characterization of insulin-mimetic inositol phosphoglycan-like molecules from grass pea (Lathyrus sativus) seeds. Mol Med 2001;7:454–460.
Huang LC, Fonteles MC, Houston DB, Zhang C, Larner J: Chiroinositol deficiency and insulin resistance. III. Acute glycogenic and hypoglycemic effects of two inositol phosphoglycan insulin mediators in normal and streptozotocin-diabetic rats in vivo. Endocrinology 1993;132:652–657.
Fonteles MC, Almeida MQ, Larner J: Antihyperglycemic effects of 3-O-methyl-D-chiro-inositol and D-chiro-inositol associated with manganese in streptozotocin diabetic rats. Horm Metab Res 2000;32:129–132.
Kim MJ, Yoo KH, Kim JH, et al: Effect of pinitol on glucose metabolism and adipocytokines in uncontrolled type 2 diabetes. Diabetes Res Clin Pract 2007;77(suppl 1):S247–251.
Bon Jeong Ku, Hyun Jin Kim, Kang Seo Park: The clinical study to evaluate the safety and efficacy of D-chiro-inositol patients with type 2 diabetes. The Korean Journal of Medicine 2007;72:28–36.
Ortmeyer HK, Larner J, Hansen BC: Effects of D-chiroinositol added to a meal on plasma glucose and insulin in hyperinsulinemic rhesus monkeys. Obes Res 1995;3(suppl 4):605S–608S.
Davis A, Christiansen M, Horowitz JF, Klein S, Hellerstein MK, Ostlund RE Jr: Effect of pinitol treatment on insulin action in subjects with insulin resistance. Diabetes Care 2000;23:1000–1005.
Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ, Burrell MA: The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab 2001;280:E827–E847.
Yamauchi T, Kamon J, Waki H, et al: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941–946.
Brautigan DL, Brown M, Grindrod S, et al: Allosteric activation of protein phosphatase 2C by D-chiro-inositol-galactosamine, a putative mediator mimetic of insulin action. Biochemistry 2005;44:11067–11073.
Kennington AS, Hill CR, Craig J, et al: Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1990;323:373–378.
Suzuki S, Kawasaki H, Satoh Y, et al: Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type II diabetes. Diabetes Care 1994;17:1465–1468.
Cheang KI, Baillargeon JP, Essah PA, et al: Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism 2008;57:1390–1397.
Kim JI, Kim JC, Kang MJ, Lee MS, Kim JJ, Cha IJ: Effects of pinitol isolated from soybeans on glycaemic control and cardiovascular risk factors in Korean patients with type II diabetes mellitus: a randomized controlled study. Eur J Clin Nutr 2005;59:456–458.
Li S, Shin HJ, Ding EL, van Dam RM: Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009;302:179–188.
Tabak AG, Brunner EJ, Miller MA, et al: Low serum adiponectin predicts 10-year risk of type 2 diabetes and HbA1c independently of obesity, lipids, and inflammation: Whitehall II study. Horm Metab Res 2009;41:626–629.
Fargnoli J, Sun Q, Olenczuk D, et al: Resistin is associated with biomarkers of inflammation while total and HMW adiponectin are associated with biomarkers of inflammation, insulin resistance, and endothelial function. Eur J Endocrinol 2010;162:281–288.
Szymczak E, Laskowska-Klita T: The role of leptin in human obesity. Med Wieku Rozwoj 2001;5:17–26.
Fischer S, Hanefeld M, Haffner SM, et al: Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass. Acta Diabetol 2002;39:105–110.
Miyazaki Y, DeFronzo RA: Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metab 2008;10:1204–1211.
Otto C, Otto B, Goke B, et al: Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulin resistance as well as ghrelin and resistin levels. J Endocrinol Invest 2006;29:231–236.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.